DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA
BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

a 2024

DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

ČIMBOROVÁ, Katarína, Vendula PELKOVÁ, Tereza SOURALOVÁ, Naděžda VAŠKOVICOVÁ, Tomáš BÁRTA et. al.

Basic information

Original name

DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS

Authors

ČIMBOROVÁ, Katarína (703 Slovakia, belonging to the institution), Vendula PELKOVÁ (203 Czech Republic, belonging to the institution), Tereza SOURALOVÁ (203 Czech Republic, belonging to the institution), Naděžda VAŠKOVICOVÁ (203 Czech Republic, belonging to the institution), Tomáš BÁRTA (203 Czech Republic), Irena KOUTNÁ (203 Czech Republic, belonging to the institution) and Aleš HAMPL (203 Czech Republic, guarantor, belonging to the institution)

Edition

SY-Stem 2024, Vienna, 2024

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10605 Developmental biology

Country of publisher

Austria

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

Keywords in English

macular degeneration; retina derivates; human pluripotent cells

Abstract

V originále

Regenerative medicine in the field of ophthalmology was revolutionized in the 1990s through stem cell-based therapies focusing on treating corneal diseases1. However, there still exist numerous incurable diseases associated with the perceptive part itself, the retina. The pathogenesis of the multiple forms of retinopathies is often associated with the dysfunction and loss of retinal cell types, including retinal pigment epithelium (RPE). Our objective is, thus, to establish for the first time in the Czech Republic the current Good Manufacturing Practise (cGMP) compliant methodological and regulatory grounds for producing a key component of the Advanced Therapy Medicinal Product – human pluripotent stem cell-derived RPE cells2. By doing so, we aim to contribute to the advancement of regenerative medicine, particularly in the treatment of retinal diseases. In our ongoing research, we have determined the optimal conditions for differentiation of hPSC into RPE cells, utilizing established protocols as a foundational reference. We have started with the establishment of the morphological, molecular, and functional criteria to assess the efficacy of the differentiation process, alongside a comprehensive evaluation of the genetic stability to ensure their safety. Our next steps involve the crucial transfer of this methodology to cGMP conditions, laying the groundwork for the translation of our findings into the realm of clinical applications.

Links

MUNI/A/1598/2023, interní kód MU

Name: Zdroje pro tkáňové inženýrství 14

Investor: Masaryk University, Resources pro tissue engineering 14

NU22-08-00629, research and development project

Name: Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk

Investor: Ministry of Health of the CR, Subprogram 1 - standard

Citovat

ČIMBOROVÁ, Katarína, Vendula PELKOVÁ, Tereza SOURALOVÁ, Naděžda VAŠKOVICOVÁ, Tomáš BÁRTA, Irena KOUTNÁ and Aleš HAMPL. DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS. In SY-Stem 2024, Vienna. 2024.

@proceedings{2415958,
   author = {Čimborová, Katarína and Pelková, Vendula and Souralová, Tereza and Vaškovicová, Naděžda and Bárta, Tomáš and Koutná, Irena and Hampl, Aleš},
   booktitle = {SY-Stem 2024, Vienna},
   keywords = {macular degeneration; retina derivates; human pluripotent cells},
   language = {eng},
   title = {DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS},
   year = {2024}
}

TY  - CONF
ID  - 2415958
AU  - Čimborová, Katarína - Pelková, Vendula - Souralová, Tereza - Vaškovicová, Naděžda - Bárta, Tomáš - Koutná, Irena - Hampl, Aleš
PY  - 2024
TI  - DEVELOPMENT TOWARDS THERAPY OF MACULAR DEGENERATION OF RETINA BY DERIVATIVES OF HUMAN PLURIPOTENT STEM CELLS
KW  - macular degeneration
KW  - retina derivates
KW  - human pluripotent cells
N2  - Regenerative medicine in the field of ophthalmology was revolutionized in the 1990s through stem cell-based therapies focusing on treating corneal diseases1. However, there still exist numerous incurable diseases associated with the perceptive part itself, the retina. The pathogenesis of the multiple forms of retinopathies is often associated with the dysfunction and loss of retinal cell types, including retinal pigment epithelium (RPE). Our objective is, thus, to establish for the first time in the Czech Republic the current Good Manufacturing Practise (cGMP) compliant methodological and regulatory grounds for producing a key component of the Advanced Therapy Medicinal Product – human pluripotent stem cell-derived RPE cells2. By doing so, we aim to contribute to the advancement of regenerative medicine, particularly in the treatment of retinal diseases. In our ongoing research, we have determined the optimal conditions for differentiation of hPSC into RPE cells, utilizing established protocols as a foundational reference. We have started with the establishment of the morphological, molecular, and functional criteria to assess the efficacy of the differentiation process, alongside a comprehensive evaluation of the genetic stability to ensure their safety. Our next steps involve the crucial transfer of this methodology to cGMP conditions, laying the groundwork for the translation of our findings into the realm of clinical applications.
ER  -

Detailed Information on Publication Record